Chunrong Yu

Title: The Innovative Contributions of Chunrong Yu

Introduction

Chunrong Yu is a notable inventor based in Richmond, VA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patenting efforts. His work focuses on the combination of specific compounds to enhance therapeutic efficacy against resistant forms of leukemia.

Latest Patents

Chunrong Yu holds a patent for a combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, particularly flavopiridol, aimed at treating cancer. The patent describes a combination for simultaneous, separate, or sequential use that includes a cyclin-dependent kinase inhibitor and a specific compound, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. This invention is particularly relevant for treating Bcr/Abl leukemia that is resistant to the compound of formula I.

Career Highlights

Throughout his career, Chunrong Yu has worked with esteemed organizations, including the United States Government as represented by the Department of Veterans Affairs and Virginia Commonwealth University. His work in these institutions has allowed him to contribute to significant advancements in cancer research and treatment.

Collaborations

Chunrong Yu has collaborated with notable colleagues such as Paul Dent and Steven Grant. These partnerships have further enriched his research and development efforts in the field of oncology.

Conclusion

Chunrong Yu's innovative work and patent in cancer treatment exemplify the impact of dedicated research in the medical field. His contributions continue to pave the way for advancements in therapies for resistant forms of leukemia.